Meeting
2013 ASCO Annual Meeting
BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer.
Authors
Philip C. Schouten
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Philip C. Schouten , Sabine C. Linn , Sebastian Aulmann , Hans-Peter Sinn , Andreas Schneeweiss , Frederik Marme
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 11023)
DOI
10.1200/jco.2013.31.15_suppl.11023
Abstract #
11023
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.
First Author: Philip C. Schouten
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring
Poster
2014 ASCO Annual Meeting
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
First Author: Karen A. Gelmon